Inhibitors of IAP/XIAP enhance activity of sacituzumab govitecan
Ming Zhao, Bailiang Wang, Kurt W. Evans, Stephan Scott et autres
us (code pays fourni par la source)
0 citations
JNCI Journal of the National Cancer Institute
Argun Akçakanat
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
245Publications signalées
4485Citations signalées
1Affiliations récentes
Les institutions déclarées
Les domaines associés
PI3K/AKT/mTOR signaling in cancerCancer Genomics and DiagnosticsPARP inhibition in cancer therapyCancer, Lipids, and MetabolismHER2/EGFR in Cancer Research
Les publications récentes
Abstract 6761: Antitumor activity of datopotamab deruxtecan in a co-clinical trial with patient derived xenografts
Dhruv Chachad, Kurt W. Evans, Ming Zhao, Erkan Yuca et autres
us, de (code pays fourni par la source)
0 citations
Cancer Research
Abstract 356: Rezatapopt and KRAS inhibitors for the treatment of TP53 Y220C and KRAS mutant cancers.
Argun Akçakanat, Ecaterina E. Dumbrava, Kurt W. Evans, Ran Zhang et autres
us (code pays fourni par la source)
0 citations
Cancer Research
Abstract 6070: Clinical and genomic determinants of PDX engraftment across solid tumors
Leva Gorji, Kurt W. Evans, Xiaofeng Zheng, Erkan Yuca et autres
us (code pays fourni par la source)
0 citations
Cancer Research
Supplementary Table 1 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Kaushik Varadarajan, Christian X. Cruz Pico, Kurt W. Evans, Maria Gabriela Raso et autres
0 citations
Supplementary Figure 5 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Kaushik Varadarajan, Christian X. Cruz Pico, Kurt W. Evans, Maria Gabriela Raso et autres
0 citations
Supplementary Figure 6 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Kaushik Varadarajan, Christian X. Cruz Pico, Kurt W. Evans, Maria Gabriela Raso et autres
0 citations
Supplementary Figure 1 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Kaushik Varadarajan, Christian X. Cruz Pico, Kurt W. Evans, Maria Gabriela Raso et autres
0 citations
Supplementary Figure 7 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Kaushik Varadarajan, Christian X. Cruz Pico, Kurt W. Evans, Maria Gabriela Raso et autres
0 citations
Supplementary Table 4 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Kaushik Varadarajan, Christian X. Cruz Pico, Kurt W. Evans, Maria Gabriela Raso et autres
0 citations
Supplementary Figure 8 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Kaushik Varadarajan, Christian X. Cruz Pico, Kurt W. Evans, Maria Gabriela Raso et autres
0 citations
Supplementary Table 3 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations
Kaushik Varadarajan, Christian X. Cruz Pico, Kurt W. Evans, Maria Gabriela Raso et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.